Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in acute rheumatic fever (AGRAF-2)
PACTR202504487625242Phase 2Recruiting
- Sponsor
- Fondation Coeur et Arteres
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in rheumatic fever (RF) comparing Rituximab plus standard of care with Standard of care alone (2 arms). Primary endpoint: Rheumatic valvular lesions rate. Started Dec 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
rheumatic fever (RF)
Beyond the preview
Go deeper on PACTR202504487625242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202504487625242.